Also trades as: PPCBD (OTC) · $vol 0M
PPCB NASDAQ
Propanc Biopharma, Inc.
1W: -11.1%
1M: +1519.7%
3M: +857.1%
YTD: +251.6%
1Y: -31.4%
3Y: +402.5%
5Y: -99.2%
$2.01
+0.01 (+0.25%)
Weekly Expected Move ±15.1%
$0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.8M
52W Range1.5557-270.25
Volume158,791
Avg Volume137,312
Beta3.40
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOJames Nathanielsz
Employees1
SectorHealthcare
IndustryBiotechnology
IPO Date2012-11-12
Websitepropanc.com
302, 6 Butler Street
Camberwell, VIC 3124
AU
Camberwell, VIC 3124
AU
61 3 9882 0780
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Latest News
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
12 Health Care Stocks Moving In Friday's Pre-Market Session
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Kenyon Julian Norman | A-Award | 3,420,000 | — | 2021-08-17 |
| Nathanielsz James An | A-Award | 5,928,000 | — | 2021-08-17 |
| Nathanielsz James An | A-Award | 2,800,000 | — | 2021-08-17 |
| ZELINGER JOSEF | 0 | — | 2021-08-17 | |
| Campiciano Carlo M | 0 | — | 2019-06-24 |